2022
Gait Variability to Phenotype Common Orthopedic Gait Impairments Using Wearable Sensors
Kushioka J, Sun R, Zhang W, Muaremi A, Leutheuser H, Odonkor C, Smuck M. Gait Variability to Phenotype Common Orthopedic Gait Impairments Using Wearable Sensors. Sensors 2022, 22: 9301. PMID: 36502003, PMCID: PMC9739785, DOI: 10.3390/s22239301.Peer-Reviewed Original ResearchConceptsStride length variabilityGait impairmentDisease groupGait parametersGait variabilityHigher stride length variabilityMobility impairmentsMin walk testDifferent pathologiesGait variability measuresAge-related degenerative diseasesWalk testNeurologic impairmentCommon symptomsGait rhythmicityHealthy controlsLSS groupGait differencesHealthy individualsLength variabilityPotential biomarkersMobility disordersSpecific pathologyDegenerative diseasesImpairment
2021
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
Briot K, Portale AA, Brandi ML, Carpenter TO, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Ing S, Insogna K, Ito N, de Beur S, Javaid MK, Kamenicky P, Keen R, Kubota T, Lachmann RH, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Nixon A, Nixon M, Sun W, Williams A, Imel EA. Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open 2021, 7: e001714. PMID: 34548383, PMCID: PMC8458321, DOI: 10.1136/rmdopen-2021-001714.Peer-Reviewed Original ResearchConceptsBrief Pain Inventory-Short FormPatient-reported outcomesBrief Fatigue InventoryBPI-SF scoresAmbulatory functionWeek 96Burosumab treatmentMcMaster Universities Osteoarthritis IndexOpen-label extensionDouble-blinded trialPhase 3 trialMin walk testSignificant improvementWOMAC stiffnessOsteoarthritis IndexWeek 48Worse fatigueWeek 24Walk testFatigue InventoryWestern OntarioBFI scoresSubstantial burdenWOMACBurosumab
2019
The China Patient-centred Evaluative Assessment of Cardiac Events (PEACE) prospective heart failure study design
Huang X, Yu Y, Li X, Masoudi FA, Spertus JA, Yan X, Krumholz HM, Jiang L, Li J. The China Patient-centred Evaluative Assessment of Cardiac Events (PEACE) prospective heart failure study design. BMJ Open 2019, 9: e025144. PMID: 30782925, PMCID: PMC6377534, DOI: 10.1136/bmjopen-2018-025144.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesHeart failureChina PatientMedical historyCardiac Events Prospective Heart Failure StudyDisease-specific health statusEthics CommitteeCardiovascular risk factorsProspective cohort studyMin walk testHeart Failure StudyPatient's medical historyLocal ethics committeeQuality of careCollection of bloodHF hospitalisationHospitalisation eventsHospital outcomesCohort studyPatient demographicsTransthoracic echocardiogramWalk testHospital treatmentMedical recordsRisk factors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply